The results are a boost to Novo Nordisk after another weight-loss therapy, CagriSema (cagrilintide and semaglutide), delivered lower-than-hoped-for weight loss of 20.4% at 68 weeks in a phase 3 ...

Novo Nordisk’s bid to provide a once-weekly basal insulin product for people with diabetes, reducing the number of injections needed, has hit a major hurdle in the US. The FDA sent the Danish ...

Real time quote data is not available at this time. *Data is provided by Barchart.com. Data reflects weightings calculated at the beginning of each month. Data is subject to change. **Green ...